C
CCCC
C4 Therapeutics, Inc.
2.47
-0.07-2.76%After Hours: 2.470 0.00 0.00%17:31 12/12 EST
OPEN/PREV CLOSE2.550/2.540
TODAY RANGE2.460-2.570
VOL1.29M
MARKET CAP239.38M
52 WEEK RANGE1.085-5.10
AVG VOL (3M)2.10M
% TURNOVER1.33%
TURNOVER--
P/E (TTM)-1.4782
% RANGE4.33%
EPS(TTM)-1.6709
P/E(FORWARD)-1.8296
P/B1.187
BVPS2.082
DIVIDEND--
P/S4.903
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP208.57M
SHARES OUTSTANDING96.91M
NEXT EARNINGS02/25-03/02
FREE FLOAT84.44M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·12/02 17:31
This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
Benzinga·12/02 13:55
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Dow Jones·12/02 12:30
C4 Therapeutics Initiated at Buy by TD Cowen
Benzinga·12/02 12:20
TD Cowen Initiates Coverage On C4 Therapeutics with Buy Rating
TipRanks·12/02 10:40
C4 Therapeutics initiated with a Buy at TD Cowen
Reuters·12/02 07:06
U.S. RESEARCH ROUNDUP- Green Brick Partners, Pultegroup, Toll Brothers
Seeking Alpha·11/26 11:27
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss
Reuters·11/25 12:00
C4 Therapeutics to Participate in Evercore Healthcare Conference
TipRanks·11/21 21:10
C4 Therapeutics files $400M mixed securities shelf
Benzinga·11/21 21:08
C4 Therapeutics Files For Mixed Shelf Of Up To $400M
Reuters·11/21 21:04
C4 THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $400 MLN - SEC FILING
Seeking Alpha·11/12 15:16
Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors
TipRanks·11/07 09:37
Barclays Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)
TipRanks·11/07 04:28
C4 Therapeutics Reports Q3 2025 Financial Results
Same Industry
Name/Symbol
Change%
Price